The agreement aims to generate and disseminate knowledge about biosimilars for medical professionals. The two associations have committed to establishing a system of exchange of information related to scientific and clinical knowledge, which they say will allow for educational and informative actions of joint interest. They will also offer recommendations and updated information in a joint manner, addressed to different health partners.

The joint working group will include the scientific-medical societies that are part of FACME, as well as others, that represent a group of specialists linked to the use and prescription of biosimilars.

Dr Fernando Carballo, President of FACME, said that ‘prescribing physicians should be an essential part in the process of discussion and adoption of agreements and decisions aimed at rationalizing the use of biologicals, including the use of biosimilars’. Likewise, the President of BioSim, Joaquín Rodrigo, underlined the fact that ‘the quality and effectiveness of treatments with biosimilars offer every day great opportunities to benefit patients’.

Related article
Spanish gastroenterologists update biosimilar position statement

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.